Previous close | 108.00 |
Open | 108.10 |
Bid | 107.95 x N/A |
Ask | 108.45 x N/A |
Day's range | 108.10 - 108.25 |
52-week range | 86.46 - 121.90 |
Volume | |
Avg. volume | 1 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 22 July 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science mega campuses in AAA innovation cluster locations, today announced that a top 20 pharmaceutical company and longstanding credit tenant has increased its San Diego footprint by nearly 53% with the execution of a 10-year lease for 127,382 RSF, with significant expansion options, for a new R&D center at 10075 Barnes Canyon Road on the S
Alexandria (ARE) is likely to benefit from the solid demand for top-quality life science assets in key markets. However, a vast development outlay amid high interest rates is concerning.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Alexandria Real Estate Equities (ARE) have what it takes? Let's find out.